Sobi lifts 2026 revenue growth outlook after 16% third-quarter gain
Sobi reported 16% constant-currency revenue growth in Q3 and raised its full-year outlook to high-teens to low-20s, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Swedish Orphan Biovitrum (Sobi) reported third-quarter 2026 revenue up 16% at constant exchange rates, to SEK 9,124 million. Haematology was the main driver, with sales rising 29% at CER. The adjusted EBITA margin reached 45%.
The company raised its full-year 2026 revenue growth guidance to high-teens to low-20s at CER. Excluding seasonal RSV royalties, third-quarter growth was 26%, and nine-month growth reached 23%. Adjusted EBITA margin guidance was left unchanged.
why it matters
For investors, the report points to strong momentum in the core haematology franchise and higher revenue expectations for the year. Keeping margin guidance unchanged suggests faster sales growth is not being offset by concessions on profitability, which keeps the company in focus for pharma sector watchers.
market impact
Sobi and Swedish pharma: strong quarter and higher outlook support the company's shares
tags
instruments
sources
- SOBI: Revenue grew 16% at CER; FY growth guidance rose to high-teens to low-20s — TradingView, 27 October 2026 at 07:43 UTC
- SOBI: Q3 momentum lifted full-year revenue guidance to high-teens to low-20s growth at CER — TradingView, 27 October 2026 at 07:49 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗